{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T17:19:43Z","timestamp":1767633583104,"version":"3.48.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"DOI":"10.7759\/cureus.100823","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:59:29Z","timestamp":1767617969000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment of Extragenital Lichen Sclerosus With Roflumilast 0.3% Cream: A Report of Two Cases"],"prefix":"10.7759","author":[{"given":"Serena","family":"Dienes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene","family":"Dytoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13890","article-title":"Extragenital lichen sclerosus: a comprehensive review","volume":"63","author":"Arif T","year":"2022","unstructured":"Arif T, Fatima R, Sami M. Extragenital lichen sclerosus: a comprehensive review. Australas J Dermatol. 2022, 63:452-62. 10.1111\/ajd.13890","journal-title":"Australas J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.369","article-title":"An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of microRNA-155","volume":"132","author":"Terlou A","year":"2012","unstructured":"Terlou A, Santegoets LA, van der Meijden WI, et al.. An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of microRNA-155. J Invest Dermatol. 2012, 132:658-66. 10.1038\/jid.2011.369","journal-title":"J Invest Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.01.027","article-title":"Assessment of the cutaneous hormone landscapes and microbiomes in vulvar lichen sclerosus","volume":"144","author":"Pyle HJ","year":"2024","unstructured":"Pyle HJ, Evans JC, Artami M, et al.. Assessment of the cutaneous hormone landscapes and microbiomes in vulvar lichen sclerosus. J Invest Dermatol. 2024, 144:1808-16.e11. 10.1016\/j.jid.2024.01.027","journal-title":"J Invest Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04288.x","article-title":"Lichen sclerosus of lips: a clinical and histopathologic study of 27 cases","volume":"49","author":"Attili VR","year":"2010","unstructured":"Attili VR, Attili SK. Lichen sclerosus of lips: a clinical and histopathologic study of 27 cases. Int J Dermatol. 2010, 49:520-5. 10.1111\/j.1365-4632.2010.04288.x","journal-title":"Int J Dermatol"},{"key":"ref5","article-title":"Clinicopathologic comparison of vulvar and extragenital lichen sclerosus: histologic variants, evolving lesions, and etiology of 141 cases","volume":"11","author":"Carlson JA","year":"1998","unstructured":"Carlson JA, Lamb P, Malfetano J, Ambros RA, Mihm MC Jr. Clinicopathologic comparison of vulvar and extragenital lichen sclerosus: histologic variants, evolving lesions, and etiology of 141 cases. Mod Pathol. 1998, 11:844-54.","journal-title":"Mod Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2011.05.004","article-title":"Lichen sclerosus and squamous cell carcinoma","volume":"103","author":"Guti\u00e9rrez-Pascual M","year":"2012","unstructured":"Guti\u00e9rrez-Pascual M, Vicente-Mart\u00edn FJ, L\u00f3pez-Estebaranz JL. Lichen sclerosus and squamous cell carcinoma. Actas Dermosifiliogr. 2012, 103:21-8. 10.1016\/j.adengl.2011.05.004","journal-title":"Actas Dermosifiliogr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.844314","article-title":"Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression","volume":"25","author":"Levin E","year":"2014","unstructured":"Levin E, Gupta R, Butler D, Chiang C, Koo JY. Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression. J Dermatolog Treat. 2014, 25:501-6. 10.3109\/09546634.2013.844314","journal-title":"J Dermatolog Treat"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.02.019","article-title":"A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus","volume":"71","author":"Funaro D","year":"2014","unstructured":"Funaro D, Lovett A, Leroux N, Powell J. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2014, 71:84-91. 10.1016\/j.jaad.2014.02.019","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.235","article-title":"Pulsed high-dose corticosteroids combined with low-dose methotrexate treatment in patients with refractory generalized extragenital lichen sclerosus","volume":"145","author":"Kreuter A","year":"2009","unstructured":"Kreuter A, Tigges C, Gaifullina R, Kirschke J, Altmeyer P, Gambichler T. Pulsed high-dose corticosteroids combined with low-dose methotrexate treatment in patients with refractory generalized extragenital lichen sclerosus. Arch Dermatol. 2009, 145:1303-8. 10.1001\/archdermatol.2009.235","journal-title":"Arch Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.118552","article-title":"Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study","volume":"46","author":"Kreuter A","year":"2002","unstructured":"Kreuter A, Gambichler T, Avermaete A, et al.. Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study. J Am Acad Dermatol. 2002, 46:251-5. 10.1067\/mjd.2002.118552","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13473","article-title":"Methotrexate for the treatment of recalcitrant genital and extragenital lichen sclerosus: a retrospective series","volume":"33","author":"Cuellar-Barboza A","year":"2020","unstructured":"Cuellar-Barboza A, Bashyam AM, Ghamrawi RI, Aickara D, Feldman SR, Pichardo RO. Methotrexate for the treatment of recalcitrant genital and extragenital lichen sclerosus: a retrospective series. Dermatol Ther. 2020, 33:e13473. 10.1111\/dth.13473","journal-title":"Dermatol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_261_24","article-title":"Roflumilast in dermatology: a newer phosphodiesterase-4 inhibitor","volume":"70","author":"Singh S","year":"2025","unstructured":"Singh S, Paul D, Snehal A. Roflumilast in dermatology: a newer phosphodiesterase-4 inhibitor. Indian J Dermatol. 2025, 70:38-41. 10.4103\/ijd.ijd_261_24","journal-title":"Indian J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.030","article-title":"Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial","volume":"91","author":"Stein Gold L","year":"2024","unstructured":"Stein Gold L, Adam DN, Albrecht L, et al.. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial. J Am Acad Dermatol. 2024, 91:273-80. 10.1016\/j.jaad.2024.03.030","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.3121","article-title":"Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials","volume":"160","author":"Simpson EL","year":"2024","unstructured":"Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al.. Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials. JAMA Dermatol. 2024, 160:1161-70. 10.1001\/jamadermatol.2024.3121","journal-title":"JAMA Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1136","article-title":"Roflumilast foam, 0.3%, for psoriasis of the scalp and body: the ARRECTOR phase 3 randomized clinical trial","volume":"161","author":"Gooderham MJ","year":"2025","unstructured":"Gooderham MJ, Alonso-Llamazares J, Bagel J, et al.. Roflumilast foam, 0.3%, for psoriasis of the scalp and body: the ARRECTOR phase 3 randomized clinical trial. JAMA Dermatol. 2025, 161:698-706. 10.1001\/jamadermatol.2025.1136","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.20220801","article-title":"Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia","volume":"69","author":"Li L","year":"2023","unstructured":"Li L. Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia. Rev Assoc Med Bras (1992). 2023, 69:97-100. 10.1590\/1806-9282.20220801","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad041","article-title":"Severe and therapeutic challenging oral erosive lichen planus treated with oral roflumilast","volume":"48","author":"Fage S","year":"2023","unstructured":"Fage S, Johansen C. Severe and therapeutic challenging oral erosive lichen planus treated with oral roflumilast. Clin Exp Dermatol. 2023, 48:556-7. 10.1093\/ced\/llad041","journal-title":"Clin Exp Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05428-w","article-title":"Apremilast for genital erosive lichen planus in women (the AP-GELP study): study protocol for a randomised placebo-controlled clinical trial","volume":"22","author":"Skullerud KH","year":"2021","unstructured":"Skullerud KH, Gjersvik P, Pripp AH, Qvigstad E, Helgesen AL. Apremilast for genital erosive lichen planus in women (the AP-GELP study): study protocol for a randomised placebo-controlled clinical trial. Trials. 2021, 22:469. 10.1186\/s13063-021-05428-w","journal-title":"Trials"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.10.597","article-title":"Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors","volume":"145","author":"Wang J","year":"2025","unstructured":"Wang J, Ho M, Bunick CG. Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors. J Invest Dermatol. 2025, 145:1471-88.e1. 10.1016\/j.jid.2024.10.597","journal-title":"J Invest Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.25251\/skin.8.6.15","article-title":"The treatment of lichen sclerosus with topical roflumilast 0.3% case study","volume":"8","author":"Domingues E","year":"2024","unstructured":"Domingues E. The treatment of lichen sclerosus with topical roflumilast 0.3% case study. J Skin. 2024, 8:1997-2000. 10.25251\/skin.8.6.15","journal-title":"J Skin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440886-successful-treatment-of-extragenital-lichen-sclerosus-with-roflumilast-03-cream-a-report-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:59:30Z","timestamp":1767617970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440886-successful-treatment-of-extragenital-lichen-sclerosus-with-roflumilast-03-cream-a-report-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.100823","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}